GlassScriptPhysician profile
Anthony D Marinelli
NPI 1972526085
$2,497.63
in general payments reported to CMS, 2019-2025
18 companies · $649 in 2025
The $649 reported for 2025 was more than what 83% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $74.17 · 2020: $150 · 2021: $318 · 2022: $264 · 2023: $580 · 2024: $463 · 2025: $649.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,567 · Entertainment: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,566.86 |
| Entertainment | $125.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $257.07 | 2023-2025 | Tyrvaya |
| Sun Pharmaceutical Industries INC. | $234.15 | 2021-2025 | Cequa |
| Bausch & Lomb Americas INC. | $216.70 | 2022-2024 | Miebo, Vyzulta |
| Tarsus Pharmaceuticals, INC. | $211.27 | 2024-2025 | Xdemvy |
| Genzyme Corporation | $205.57 | 2019-2022 | |
| Lkc Technologies, INC. | $130.15 | 2025 | |
| Optos, INC. | $125.48 | 2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Biotissue Holdings INC. | $125.00 | 2023 | |
| Horizon Therapeutics Plc | $120.57 | 2023 | Tepezza |
| Dompe US, INC. | $120.06 | 2025 | Oxervate |
| Kala Pharmaceuticals, INC. | $118.39 | 2021 | |
| Amgen INC. | $117.56 | 2024 | Tepezza |
| Glaukos Corporation | $111.14 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $99.65 | 2020 | |
| Coopervision INC. | $87.98 | 2024 | Misight Contact Lens |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $85.18 | 2021 | |
| Harrow Eye, LLC | $81.58 | 2025 | Vevye |
| Visioneering Technologies, INC. | $50.13 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Marinelli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.